In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.

scientific article published on 06 June 2016

In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/AAC.00382-16
P932PMC publication ID4958183
P698PubMed publication ID27270290

P50authorPeter Skewes-CoxQ38155159
Pavel A NikitinQ62926684
Andrea CarfìQ88702827
P2093author name stringDavid T Barkan
Brigitte Wiedmann
Weidong Zhong
Adam Feire
Claudio Ciferri
James J Lin
Hetalkumar D Patel
Nadine Jarousse
Christy M Hebner
Tahmineh Akbarnejad Yazdi
Thomas Gesner
P2860cites workVaccine prevention of maternal cytomegalovirus infectionQ24645631
A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infectionQ27329077
Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complexQ33558361
HCMV spread and cell tropism are determined by distinct virus populationsQ33798083
High-content screening to distinguish between attachment and post-attachment steps of human cytomegalovirus entry into fibroblasts and epithelial cellsQ33806689
Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropismQ34212879
Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibodyQ34317887
A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.Q34413309
Human Cytomegalovirus gH/gL/gO Promotes the Fusion Step of Entry into All Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a Distinct MechanismQ35913890
Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody.Q36084954
Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulinQ36155456
Preliminary evaluation of the safety and efficacy of standard intravenous immunoglobulins in pregnant women with primary cytomegalovirus infectionQ36505218
Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infectionQ36973592
Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in transQ36974741
Cytomegalovirus cell tropism.Q37219958
Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipientsQ37225866
How we treat cytomegalovirus in hematopoietic cell transplant recipientsQ37237427
An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge ModelQ37508272
How to trigger a killer: modulation of natural killer cell reactivity on many levelsQ38245101
Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.Q39468421
Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virionsQ39472513
Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologsQ39686594
Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytesQ39960937
Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replicationQ42282199
Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirusQ42284197
Antibodies to Recombinant-Derived Glycoprotein B after Natural Human Cytomegalovirus Infection Correlate with Neutralizing ActivityQ43517822
Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantationQ43682605
Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection.Q45396472
Molecular epidemiology of envelope glycoprotein H of human cytomegalovirusQ48160552
Analysis of Interstrain Variation in Cytomegalovirus Glycoprotein B Sequences Encoding Neutralization-Related EpitopesQ48224220
Passive Immunization during Pregnancy for Congenital Cytomegalovirus InfectionQ55982678
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft modelQ77555291
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectCytomegalovirusQ6946
monoclonal antibodyQ422248
P1104number of pages11
P304page(s)4961-4971
P577publication date2016-07-22
P1433published inAntimicrobial Agents and ChemotherapyQ578004
P1476titleIn Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539
P478volume60

Reverse relations

cites work (P2860)
Q60960338A Native Human Monoclonal Antibody Targeting HCMV gB (AD-2 Site I)
Q90062923Advances in the Development of Therapeutics for Cytomegalovirus Infections
Q47143843Antibody therapies for the prevention and treatment of viral infections.
Q89517194Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
Q38926265Prospects of a vaccine for the prevention of congenital cytomegalovirus disease
Q59812989Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34 Cells
Q92511027The N Terminus of Human Cytomegalovirus Glycoprotein O Is Important for Binding to the Cellular Receptor PDGFRα
Q38764543Use of broadly neutralizing antibodies for HIV-1 prevention

Search more.